The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990.

Through integrated and comprehensive programs, MD Anderson advances transformative discovery, prevention, translational and clinical research. We aim to provide a deeper understanding of all cancer types, including rare cancers not often studied or treated elsewhere, to ultimately lead to meaningful benefits for patients and society. In fiscal year 2024, MD Anderson invested $1.3 billion in research efforts. MD Anderson also is home to world’s largest oncology clinical trials program, with more than 1,500 ongoing trials in FY24, and 27 drugs tested at MD Anderson received FDA approval in FY24.

Through partnership with our patients, our scientists and clinicians seamlessly collaborate to develop breakthroughs that transform the field. Discoveries from our labs are swiftly translated into new therapies in the clinic, and insights from the clinic inform our laboratory work in real time. At every step, a rapidly growing team of data scientists provide insights, processes and tools that better inform and accelerate studies. Our culture of collaboration provides early-career researchers accessible mentorship and hands-on training from some of the most brilliant minds in the world across the spectrum of cancer research and care.

Latest from The University of Texas MD Anderson Cancer Center


Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26, 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Dr. Pemmaraju on SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasms

July 24, 2018

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasms.

Dr. Arun on Ongoing Research in Triple-Negative Breast Cancer

July 24, 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23, 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Woodward on Radiotherapy in Breast Cancer

July 13, 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses radiotherapy in breast cancer.

Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer

July 13, 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11, 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

MDM2 Inhibitor May Improve Response in AML

July 09, 2018

Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, can improve the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25, 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Tucatinib Active in Heavily Pretreated HER2+ Breast Cancer

June 13, 2018

Tucatinib used in combination with capecitabine, trastuzumab, or both agents showed promising antitumor activity in heavily pretreated women with HER2-positive breast cancer with or without brain metastases.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25, 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

April 21, 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

February 21, 2018

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

x